Rafael Kraehenmann
Clinical Researcher in Psychopharmacology
Data updated
Papers
Trials
Research Footprint
Rafael Kraehenmann appears in 13 tracked papers (2015–2022), most studied alongside Psilocybin, LSD and Placebo, across Healthy Volunteers, Neuroimaging & Brain Measures and Anxiety Disorders.
Most-cited paper: The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation (399 citations).
Frequent co-authors: Franz Vollenweider, Katrin Preller and Erich Seifritz.
Publication Landscape
How the 13 papers Blossom tracks for Rafael Kraehenmann line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Rafael Kraehenmann's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 13 of 13 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Rafael Kraehenmann publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Rafael Kraehenmann publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Rafael Kraehenmann is a clinical researcher specialising in human psychopharmacology and the neuropsychological effects of serotonergic psychedelics. His work focuses on mechanistic, experimentally controlled studies that probe how LSD and psilocybin modulate perception, waking imagery, primary-process thinking and social-cognitive processing through serotonin receptor activity. He has investigated receptor-specific contributions using pharmacological challenge designs (including manipulation of 5-HT2A and 5-HT1A signalling), and has characterised both acute phenomenology and predictors of sustained response after psychedelic experiences in naturalistic and semi-clinical settings such as mindfulness retreats.
Kraehenmann's contributions emphasise bridging subjective report, behavioural measures and neurobiological mechanisms to inform both basic science and clinical translation. Key themes in his publications include the dependence of LSD-elicited dreamlike imagery on 5-HT2A activation, the modulation of psilocybin experiences by co-administered serotonergic agents, effects on social exclusion processing and neuroimaging measures, and attempts to characterise and predict acute and longer-term responses to psilocybin in groups with anxiety-related concerns. His research advances understanding of how receptor-level pharmacology shapes psychedelic phenomenology and potential therapeutic mechanisms.
Key Impact
Noted for experimental human studies elucidating how serotonergic psychedelics (LSD, psilocybin) alter perception, cognition and social processing via 5-HT2A/1A mechanisms, linking receptor pharmacology to phenomenology and potential therapeutic effects.
Collaboration Network
15 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Rafael Kraehenmann's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Rafael Kraehenmann is associated with.